{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:49:26Z","timestamp":1790394566487,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13300-026-01868-2","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:58:08Z","timestamp":1777028288000},"page":"873-884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates"],"prefix":"10.1007","volume":"17","author":[{"given":"Imran Rashid","family":"Rangraze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Tanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Janez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Arman","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Jensterle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Munda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elhadi Eltayeb","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humam Sami","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Rashid","family":"Farooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Anas Faruk","family":"Patni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"1","key":"1868_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336.","journal-title":"N Engl J Med"},{"issue":"3","key":"1868_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med."},{"issue":"10","key":"1868_CR3","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958\u201371.","journal-title":"N Engl J Med."},{"issue":"10","key":"1868_CR4","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","volume":"31","author":"B McGowan","year":"2025","unstructured":"McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Fr\u00fchbeck G, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025;31(10):3317\u201329.","journal-title":"Nat Med"},{"issue":"5","key":"1868_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13885","volume":"26","author":"AM Sharma","year":"2025","unstructured":"Sharma AM, Birney S, Crotty M, Finer N, Segal-Lieberman G, V\u00e1zquez-Vel\u00e1zquez V, et al. Determinants of adherence to obesity medication: a narrative review. Obes Rev. 2025;26(5):e13885.","journal-title":"Obes Rev"},{"issue":"5","key":"1868_CR6","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/dom.16290","volume":"27","author":"ER Hankosky","year":"2025","unstructured":"Hankosky ER, Chinthammit C, Meeks AC, Huang A, Ward JM, Mojdami D, et al. Real world use and effectiveness of tirzepatide among individuals without type 2 diabetes: results from the Optum Market Clarity database. Diabetes Obes Metab. 2025;27(5):2810\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1868_CR7","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1111\/dom.16330","volume":"27","author":"TM Hunter Gibble","year":"2025","unstructured":"Hunter Gibble TM, Chinthammit C, Ward JM, Cappell K, Sedgley R, Bonafede M, et al. Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: results from the Veradigm\u00ae database. Diabetes Obes Metab. 2025;27(6):3185\u201394.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1868_CR8","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s13300-024-01615-5","volume":"15","author":"A Janez","year":"2024","unstructured":"Janez A, Muzurovic E, Bogdanski P, et al. Modern management of cardiometabolic continuum: from overweight\/obesity to prediabetes\/type 2 diabetes mellitus. Recommendations from the Eastern and Southern Europe diabetes and obesity expert group. Diabetes Ther. 2024;15(9):1865\u201392.","journal-title":"Diabetes Ther"},{"issue":"1","key":"1868_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48 u854rf.","journal-title":"JAMA"},{"issue":"20","key":"1868_CR10","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606\u201335.","journal-title":"Circulation"},{"issue":"10300","key":"1868_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583\u201398.","journal-title":"Lancet"},{"issue":"11","key":"1868_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11):774\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1868_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/10742484221146371","volume":"27","author":"EM Muzurovi\u0107","year":"2022","unstructured":"Muzurovi\u0107 EM, Vol\u010dan\u0161ek \u0160, Tom\u0161i\u0107 KZ, et al. Glucagon-Like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonists in the treatment of obesity\/metabolic syndrome, prediabetes\/diabetes and non-alcoholic fatty liver disease-current evidence. J Cardiovasc Pharmacol Ther. 2022;27:10742484221146371.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"1868_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2026.156494","volume":"177","author":"E Muzurovi\u0107","year":"2026","unstructured":"Muzurovi\u0107 E, Katsiki N, Vol\u010dan\u0161ek \u0160, et al. Emerging incretin- and multi-agonist-based treatments\u2014the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism. 2026;177:156494.","journal-title":"Metabolism"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01868-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01868-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01868-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:23:00Z","timestamp":1781079780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01868-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1868"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01868-2","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrej Janez has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Abbott, Novo Nordisk, Medtronic, and Sanofi. Mojca Jensterle reports receiving lecture honoraria from Novo Nordisk, Eli Lilly, Pfizer, Amgen, AstraZeneca, Novartis and Sanofi and being an advisory board member of Novo Nordisk, Eli Lilly, Amgen and Pfizer. Manfredi Rizzo has given lectures, received honoraria and research support and participated in conferences, advisory boards and clinical trials sponsored by many pharmaceutical companies, including Amgen, AstraZeneca, Biodexa, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche, Sanofi and Servier. Manfredi Rizzo is an Editorial Board member\u00a0of\u00a0Diabetes Therapy. Manfredi Rizzo was not involved in the selection\u00a0of\u00a0peer reviewers for the manuscript nor any\u00a0of\u00a0the subsequent editorial decisions. Imran Rashid Rangraze, Mohamed El-Tanani, Viviana Maggio, Syed Arman Rabbani, Ana Munda, Elhadi Eltayeb Abbas, Humam Sami Ali, Mohammad Rashid Farooqi, and Mohamed Anas Faruk Patni have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study adhered to the principles of the Declaration of Helsinki and was approved on September 5, 2024 by the institutional ethical committee of the RAK Hospital, Ras Al Khaimah (protocol n. RAKMHSU-HEC-86-2023\/24-F-M). All participants provided written informed consent for participation and for the use of anonymized data for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}